Investors

Kadimastem on Tel-Aviv Stock Exchange

For More Investors Info.

Thanks! Message sent.

Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan

July 21, 2021, 12:46:30 PM

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article

May 11, 2021, 11:30:15 AM

Kadimastem Raises NIS 22.3 Million ($6.8 Million)

April 26, 2021, 7:19:04 AM

Kadimastem Granted a Patent in Israel for the Treatment of ALS

March 9, 2021, 9:00:16 AM

Kadimastem Announces Executive Management Changes

January 31, 2021, 10:59:20 AM

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

December 15, 2020, 1:56:27 PM

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

August 3, 2020, 7:11:53 AM

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020, 1:25:35 PM

Kadimastem Announces the Completion of Treatment for Cohort B

July 27, 2020, 1:25:54 PM

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

July 27, 2020, 1:27:08 PM

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

July 27, 2020, 1:28:11 PM

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

November 17, 2019, 2:10:12 PM

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020, 1:30:03 PM

Kadimastem Announces Leadership Changes

May 20, 2019, 1:09:25 PM

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

April 18, 2019, 1:45:49 PM

Appointment of a new CFO for Kadimastem

March 3, 2019, 7:44:59 AM

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

February 24, 2019, 7:48:37 AM

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

February 17, 2019, 8:00:17 AM

Kadimastem to be included in the TASE Indices

November 27, 2018, 10:46:59 AM

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

November 14, 2018, 2:48:21 PM

Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes

November 12, 2018, 2:48:44 PM

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

November 4, 2018, 2:47:51 PM

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

October 9, 2018, 9:47:57 AM

Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

October 2, 2018, 1:47:28 PM

Kadimastem and The AFDR Selected to Receive a bi-National Grant

July 2, 2018, 1:47:12 PM

Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial

July 1, 2018, 1:46:48 PM

Kadimastem was honored with a prize for excellence for the presentation of the company's technology

June 27, 2018, 1:46:28 PM

Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:

January 7, 2019, 8:15:36 AM

Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published

June 6, 2018, 7:21:11 AM

Successful Public Offering for Kadimastem

May 15, 2018, 7:45:40 AM

Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients

April 26, 2018, 7:47:21 AM

Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes

April 21, 2018, 9:00:00 PM

Successful Rights Offering for Kadimastem; Raised NIS 5.1M

November 13, 2014, 2:45:07 PM

Kadimastem to Raise up to NIS 10M in Rights Offering

October 14, 2014, 1:40:24 PM

Kadimastem Received Response from FDA:

January 3, 2019, 2:28:35 PM

Kadimastem Approached the FDA Regarding Its ALS Treatment

October 6, 2014, 1:19:35 PM

Kadimastem to collaborate with Merck Serono to advance efforts in neurodegenerative diseases

August 3, 2014, 12:40:37 PM

Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS

June 20, 2014, 12:35:36 PM

Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS

June 18, 2014, 12:26:06 PM

Kadimastem Receives Approval for U.S. Patent

June 2, 2014, 11:28:54 AM

Leading pharma entrepreneur Avi Meizler believes in Kadimastem!

March 19, 2014, 10:23:02 AM

Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)

February 3, 2014, 10:20:55 AM

Kadimastem Augments the Company's ALS Activities

January 5, 2014, 10:11:36 AM

Kadimastem has received approval from the OCS to promote cell therapy

December 23, 2013, 10:05:45 AM

Merck Serono and Kadimastem MOU on Drug Screening and Discovery for Neurodegenerative Diseases

November 4, 2013, 10:02:26 AM

Kadimastem successfully completes an IPO and raised $5.5 Million USD

June 9, 2013, 8:59:08 AM

Pharmaceutical Company Merck Serono signs an agreement: Use Kadimastem's platform for drug screening

April 4, 2012, 8:57:29 AM

Dr. Eli Opper, joined Kadimastem's team of Advisors

February 22, 2012, 9:56:42 AM

Kadimastem appointed Mr. Ofer Haviv as a director

January 17, 2012, 9:55:40 AM

The new Chief Scientist, Mr. Avi Hasson visits Kadimastem

June 12, 2011, 8:54:49 AM